PMC7325976_01
Computed tomography (CT) scans before (A) and after (B) afatinib therapy.
fonc-10-00867-g0001.jpg
PMC7325976_01_fonc-10-00867-g0001.jpg
F1
A mass (2.3 x 1.8 cm) in the right lower lung was observed by computed tomography (CT) scan (Figure 1A). China) (Figure 3), and PD-L1 staining was not done. Therefore, he underwent oral afatinib treatment (30 mg qd). Afterwards, the patient showed a stable tumor response to afatinib (1.9 x 1.4 cm) (Figure 1B). Besides, there were no adverse events, including gastrointestinal reactions, hepatic and renal function, and cardiac damage. Currently, the disease is stable and treatment with afatinib continues for 10 months.
Hematoxylin and eosin (H&E) staining of lung biopsy showed a typical morphology for adenocarcinoma cells (H&E x 100).
fonc-10-00867-g0002.jpg
PMC7325976_01_fonc-10-00867-g0002.jpg
F2
We detected a typical morphology for adenocarcinoma cells by hematoxylin and eosin (H&E) staining (Figure 2).
The EGFR-KDD is an oncogenic EGFR alteration. (A) The Integrative Genomics Viewer snapshot of paired NGS reads of tumor and matched blood. (B) Schematic representation of EGFR-KDD depicting the genetic and protein domain structures. ECD, extracellular domain; TM, transmembrane domain; KD1, first kinase domain; KD2, second kinase domain; C-term, carboxyl terminus. Blue, EGFR exons 18-25 #1; orange, EGFR exons 18-25 #2.
fonc-10-00867-g0003.jpg
PMC7325976_01_fonc-10-00867-g0003.jpg
F3
China) (Figure 3), and PD-L1 staining was not done. Therefore, he underwent oral afatinib treatment (30 mg qd). Afterwards, the patient showed a stable tumor response to afatinib (1.9 x 1.4 cm) (Figure 1B). Besides, there were no adverse events, including gastrointestinal reactions, hepatic and renal function, and cardiac damage. Currently, the disease is stable and treatment with afatinib continues for 10 months.